The estimated Net Worth of Capital Viii, Llc Vivo Capi... is at least $14.9 million dollars as of 20 July 2018. Capital Capi owns over 353,180 units of Crinetics Pharmaceuticals Inc stock worth over $14,935,674 and over the last 6 years Capital sold CRNX stock worth over $0.
Capital has made over 1 trades of the Crinetics Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital bought 353,180 units of CRNX stock worth $6,576,212 on 20 July 2018.
The largest trade Capital's ever made was buying 353,180 units of Crinetics Pharmaceuticals Inc stock on 20 July 2018 worth over $6,576,212. On average, Capital trades about 353,180 units every 0 days since 2018. As of 20 July 2018 Capital still owns at least 294,357 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Capital Capi stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is 505 Hamilton Ave #200, Palo Alto, CA 94301, USA.
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen et Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include: